Solid Biosciences Inc. (SLDB) Earnings History
Net Loss11 years of earnings data (2015–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Solid Biosciences Inc. (SLDB) Earnings Overview
As of June 23, 2026, Solid Biosciences Inc. (SLDB) reported trailing twelve-month net income of -$192M, reflecting +35.0% year-over-year growth. The company earned $-1.75 per diluted share over the past four quarters.
Looking at the long-term picture, SLDB's historical earnings data spans multiple years. The company achieved its highest annual net income of -$6M in fiscal 2015.
Solid Biosciences Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SRPT ($65M net income, -32.5% margin), CRSP (-$569M net income, -16569.8% margin), SGMO (-$123M net income, -310.8% margin), SLDB has comparable earnings metrics. Compare SLDB vs SRPT →
SLDB Earnings vs Peers
Earnings metrics vs comparable public companies
SLDB Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$174M | -39.8% | -$179M | $-1.99 | - | - |
| 2024 | -$125M | -29.9% | -$130M | $-3.06 | - | - |
| 2023 | -$96M | -11.7% | -$104M | $-4.83 | - | - |
| 2022 | -$86M | -19.1% | -$106M | $-10.10 | -1062.3% | -1315.2% |
| 2021 | -$72M | +18.2% | -$72M | $-10.14 | -530.0% | -530.5% |
| 2020 | -$88M | +24.7% | -$86M | $-25.50 | - | - |
| 2019 | -$117M | -56.7% | -$119M | $-43.05 | - | - |
| 2018 | -$75M | -43.5% | -$76M | $-33.73 | - | - |
| 2017 | -$52M | -142.0% | -$55M | $-24.26 | - | - |
| 2016 | -$22M | -237.8% | -$26M | $-16.80 | - | - |
| 2015 | -$6M | - | -$7M | $-4.97 | - | - |
Download Data
Export SLDB earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SLDB — Frequently Asked Questions
Quick answers to the most common questions about buying SLDB stock.
What is SLDB earnings per share (EPS)?
SLDB trailing twelve-month (TTM) diluted EPS is $-1.75, reflecting +35.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2015 to 2025 is available in the table on this page.
What is Solid Biosciences Inc.'s net income?
Solid Biosciences Inc. (SLDB) trailing twelve-month net income is $-192M as of 2025. Earnings grew +35.0% year-over-year.
Is SLDB profitable?
SLDB is not currently profitable on a TTM basis, reporting a net loss of $-192M. Net margin is N/A. Investors should monitor for a return to profitability.
What is SLDB's earnings growth rate?
SLDB compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2015 to 2025.
What are SLDB's profit margins?
Solid Biosciences Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -109.9%.
Is SLDB growing earnings?
Yes, SLDB earnings are accelerating — EPS growth of +35.0% exceeds the 5-year CAGR of N/A. TTM net income reached $-192M. Earnings momentum is strengthening.
What was SLDB's best earnings year?
Solid Biosciences Inc.'s highest annual net income on record is $-6M, achieved in fiscal year 2015. Earnings history on this page spans 2015 to 2025 and includes all annual and quarterly figures.
What were SLDB's earnings last quarter?
SLDB's most recent reported quarter was Q1 2026. Net income was $-57M with diluted EPS of $-0.52. For a full breakdown of all quarters, see the quarterly earnings table on this page.